Does sacubitril/valsartan reduce the rate of eGFR decrease and improve cardiovascular outcomes compared to enalapril in patients with heart failure?
Sacubitril/valsartan provides renoprotective effects by slowing eGFR decline while improving cardiovascular outcomes in heart failure patients compared to enalapril.
Compared with enalapril, sacubitril/valsartan led to a slower rate of decrease in the eGFR and improved cardiovascular outcomes, even in patients with chronic kidney disease, despite causing a modest increase in UACR.
Damman et al. (Wed,) studied this question.